ICH E6(R3) vs ICH E8(R1): How They Work Together
How ICH E6(R3) and E8(R1) work together to support quality-by-design, risk-based oversight, and improved patient protection in clinical trials.
Safe Use of Large Language Models in Regulation (LLMs)
The EMA sets guiding principles for large language models (LLMs) in regulatory science. Learn practical safeguards and how the MyRBQM® Portal aligns.
Patient Profiles: Understand the Person Behind the Data
Learn how modern medical monitoring uses contextual patient profiles and AI-supported oversight to detect risk sooner and protect patient safety.
Drug Interaction Visualizer: Explore Drug–Drug Safety Profiles
Explore drug–drug interactions using FDA adverse event data. Search, compare, and visualize potential risks when combining commonly prescribed medications.
Clinical Trials Global & Regional Insights Visualizer
Interactive visualizer showing global and country-level clinical trial activity and patient enrollment trends across regions from 2010 to 2022.
The Real Cost of Trial Delays & How RBQM Reduces Risk
Clinical trial delays are costly. Learn updated cost estimates and how RBQM + QbD make studies more predictable, efficient, and patient-focused.
Big Pharma Mergers and Acquisitions: Clinical Trials Visualizer
Interactive visualizer showing how major pharmaceutical mergers and acquisitions relate to clinical trial activity, R&D spending, and market trends over time.
Quality Tolerance Limits (QTLs) in Clinical Trials
Quality tolerance limits (QTLs) define when trial performance risks safety or data integrity. This guide explains the 7 most important QTLs under ICH E6(R3).
R&D Efficiency: Big Pharma Overview
Explore R&D investment and innovation output across leading pharmaceutical companies through an interactive data visualizer.
Economy and Health Indicators Across OECD Countries
Interactive visualizer comparing economic indicators and health outcomes across OECD countries to support contextual understanding of population health trends.
